Espinosa, Joaquin M.
- University of Colorado · Internal Medicine (NIH department code)
From the FY2023 NIH awards this investigator leads as contact PI. The department is the award's.
FY2023 NIH rank #4,820
- Rising Star
- Long-Funded
Researcher identity and coverage
- Current affiliation
- Not verified in ScienceDex.NIH award organizations may differ from a researcher's employer.
- NIH RePORTER identity
- Profile ID unavailableSearch this ID in NIH RePORTER
- ORCID iD
- No ORCID iD on recordA researcher can add one by claiming this profile.
- ScienceDex PI coverage
- FY2006 through FY2023Career claims are limited to the years shown.Metrics use this researcher's latest loaded PI award year; ScienceDex is current through FY2026.
FY2023 award categories
- Internal Medicine
NIH Funding · FY2023
Linked Award Amount
$1.7M
Full award amounts, FY2023
Award Records
2
Records listing this PI
Award-Linked Rank
#4,820
By linked amount among FY2023 PIs
Earliest Year Loaded
2006
ScienceDex PI coverage
Award-linked funding history
Linked NIH award amounts and rank by fiscal year.
FY2023 award records by amount
NIH award records listing Espinosa, Joaquin M. as a PI. Multi-PI records show the full award amount for context.
- 5R61HD109748-02R61Contact PIMechanistic investigation of therapies for Down Syndrome Regression DisorderUniversity of Colorado · Internal Medicine (NIH department code)$1.2Maward amount
- 3R33AR077495-03S1R33Contact PIJAK Inhibition in Down SyndromeUniversity of Colorado · Internal Medicine (NIH department code)$536.7Kaward amount
Award organization
Organizations that administered FY2023 awards listing Espinosa, Joaquin M. as a PI.
FY2023 award administered by University of Colorado (CO).
Coverage and award-record milestones
Computed from the fiscal years currently available in ScienceDex.
- 2006First NIH AwardUniversity of Colorado
- 2007$500K Cumulative Funding
- 2010$1M Cumulative Funding
- 2014$2M Cumulative Funding
- 2018Entered Top 50% NationallyRanked #9980
- 2019$5M Cumulative Funding
- 2019Entered Top 25% NationallyRanked #1222
- 2019Entered Top 10% NationallyRanked #1222
- 2023$10M Cumulative Funding